ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference
ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15 th , 2017 at the Waldorf Hilton Hotel (Aldwych) in London, UK.
- Conference: Jefferies Global Healthcare Conference
- Date: November 15, 2017
- Presentation Time: 2:00 PM GMT/ 9:00 AM ET
A live webcast of the Jefferies Global Healthcare presentation will be available online from the investor relations page of the company's corporate website at www.erytech.com/webcast.com. After the live webcast, an archive of the presentation will be available on the company website for 30 days.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.
The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
Eryaspase in combination with chemotherapy achieved positive efficacy and safety results in a Phase 2/3 study in children and adults with relapsed or refractory ALL and in a Phase 2b clinical study in second-line metastatic pancreatic cancer. ERYTECH also has an ongoing Phase 1 clinical study of eryaspase in the United States in adults with newly diagnosed ALL and a Phase 2b clinical study in Europe in elderly patients with newly diagnosed acute myeloid leukemia (AML), each in combination with chemotherapy.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the NASDAQ market in the United States under the ticker ERYP. ERYTECH is also listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. .
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
The Ruth Group
+1 646 536 7012
+1 508 280 6592
+33 1 44 71 98 52
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Schlumberger Announces Third-Quarter 2018 Results Conference Call21.8.2018 17:05 | Pressemelding
Schlumberger Limited (NYSE:SLB) will hold a conference call on October 19, 2018 to discuss the results for the third quarter ending September 30, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 19, 2018, and can be accessed by dialing +1 (800) 475-6701 withi
Amazon Game Studios Announces The Grand Tour Game21.8.2018 15:00 | Pressemelding
Amazon.com (NASDAQ: AMZN) today announced that Jeremy Clarkson, Richard Hammond, and James May are bringing high-jinks and hot laps to PlayStation 4 and Xbox One in The Grand Tour Game, an episodic racing game based on the hit Prime Original series, The Grand Tour. Created by Amazon Game Studios, The Grand Tour Game transports players to exotic locations, where they'll drive the world's most interesting cars, and participate in the show's outrageous challenges. New episodes of The Grand Tour Game will be added weekly during Season 3 of the show, capturing cars, locations, and surprises from each week's episode. Visit www.playthegrandtourgame.com for more information. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005353/en/ The Grand Tour Game puts players behind the wheel of the cars from Season 3, and brings them to the iconic locations the hosts will visit this season, including The Grand Tour's signature Eboladrome
Andersen Global Expands in Africa with Oliveira & Associados21.8.2018 13:30 | Pressemelding
Andersen Global continues its expansion in Africa through a Collaboration Agreement with Oliveira & Associados, a law firm based in Angola, founded by Formosa Oliveira in 2016. Andersen Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz, commented, “The economy in Angola is one of the fastest growing in the world, and we are excited about adding this practice in a market that has a strong connection to Portugal and is strategic to our business in Portugal. Oliveira & Associados is an energetic and talented group, and with the addition of Isalcio Mahanjane e Associados in Mozambique last week, we have added key locations in our Portuguese and Iberian strategy.” With headquarters in Luanda, Oliveira & Associados provides legal services to both corporate and individual clients within Africa and globally. “Collaborating with Andersen Global will help us extend our reach as we develop and seamlessly deliver cross-border solutions,” remarked Formosa Oliveira. “With added tax and legal se
Mavenir Introduces RCS Business Messaging Partner Program to Enable MNO’s A2P Revenue Growth21.8.2018 13:00 | Pressemelding
Mavenir, the world’s #1 messaging systems provider and a leader in Rich Communication Services (RCS)—with an 85% market share in North America—today announced its RCS Business Messaging Partner Program with 15 confirmed partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005089/en/ Mavenir’s RBM Chatbot (Photo: Business Wire) The Mavenir RCS Business Messaging (RBM) solution enables brands, aggregators, content providers, enterprises and MNOs to monetize RCS messaging technologies and provide rich, multimedia end-user experiences from the native messaging application on mobile devices. This global partner program is focused on accelerating the adoption of RCS multimedia messaging by creating a community of industry leading messaging partners to provide MNOs with a compelling business-to-consumer (B2C) messaging channel and become the platform of choice for advertisers, brands, content providers and enterprises to
Dynacor Announces First Quarterly Dividend Payment21.8.2018 12:03 | Pressemelding
Dynacor Gold Mines Inc. (TSX: DNG) (OTC: DNGDF) (Dynacor or the Corporation) is pleased to announce today that its Board of Directors (Board) has approved the initiation of quarterly cash dividends to its shareholders and the declaration of the first cash dividend in the company's history. The dividend of CAD$ 0.01 per common share, is payable on October 1, 2018 to shareholders of record on September 20, 2018. Dynacor is one of the largest ore purchasing processors in Peru. With its new ore processing facility operating at near full capacity, the Corporation is forecasting 2018 to be its best year on record. Dynacor’s stable business model is proven to withstand the volatility of the gold price. The Corporation is free of debt, in a healthy financial situation and working towards its 30th consecutive quarter of profits. President and CEO Jean Martineau states, “Our team has worked very hard to build the Corporation to what it is today. Our solid financial situation and leadership posit
FAA Approves AerTrak for Boeing 757-200 Series Aircraft to Comply with Automatic Dependent Surveillance-Broadcast (ADS-B) Operations Mandate21.8.2018 12:00 | Pressemelding
The Federal Aviation Administration (FAA) has issued a Supplemental Type Certificate (STC) for installation of AerSale®’s AerTrak™ system on Boeing 757-200 series aircraft (ST04011NY), to comply with the Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule, a critical part of the agency’s Next Generation Air Transportation System (NextGen). Beginning January 1, 2020, the FAA has mandated that aircraft operating in airspace defined by 14 CFR § 91.225 must be equipped with an ADS-B Out system that meets the minimum performance requirements of 14 CFR § 91.227. The FAA approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) earlier this year. ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, an